{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T07:35:12Z","timestamp":1725694512798},"publisher-location":"Vienna","reference-count":29,"publisher":"Springer Vienna","isbn-type":[{"type":"print","value":"9783211820346"},{"type":"electronic","value":"9783709189542"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[1988]]},"DOI":"10.1007\/978-3-7091-8954-2_2","type":"book-chapter","created":{"date-parts":[[2012,7,28]],"date-time":"2012-07-28T20:55:41Z","timestamp":1343508941000},"page":"11-15","source":"Crossref","is-referenced-by-count":0,"title":["The case for and concerns about continuous dopamine stimulation in Parkinson\u2019s disease"],"prefix":"10.1007","author":[{"given":"J. G.","family":"Nutt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"2_CR1","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/BF00428198","volume":"85","author":"R Castro","year":"1985","unstructured":"Castro R, Abreu P, Calzadilla CH, Rodriguez M (1985) Increased or decreased locomotor response in rats following repeated administration of apomorphine depends on dosage interval. Psychopharmacology 85: 333\u2013339","journal-title":"Psychopharmacology"},{"key":"2_CR2","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJM197603112941101","volume":"294","author":"GC Cotzias","year":"1976","unstructured":"Cotzias GC, Papavasiliou PS, Tolosa ES, Mendez JS, Bell-Midura M (1976) Treatment of Parkinson\u2019s disease with apomorphines: Possible role of growth hormone. N Engl J Med 294: 567\u2013572","journal-title":"N Engl J Med"},{"key":"2_CR3","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1002\/ana.410040619","volume":"4","author":"L Direnfeld","year":"1978","unstructured":"Direnfeld L, Spero L, Marotta J, Seeman P (1978) The L-Dopa on-off effect in Parkinson\u2019s disease: Treatment by transient drug withdrawal and dopamine receptor resensitization. Ann Neurol 4: 573\u2013575","journal-title":"Ann Neurol"},{"key":"2_CR4","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1212\/WNL.37.7.1250","volume":"37","author":"ST Gancher","year":"1987","unstructured":"Gancher ST, Nutt JG (1987) Diurnal responsiveness to apomorphine. Neurology 37: 1250\u20131253","journal-title":"Neurology"},{"key":"2_CR5","first-page":"278","volume":"33","author":"JJ Gervas","year":"1983","unstructured":"Gervas JJ, Muradas V, Bazan E, Aguado EG, de Yebenes JG (1983) Effects of 3-OM-dopa on monoamine metabolism in rat brain. Neurology 33: 278\u2013282","journal-title":"Effects of 3-OM-dopa on monoamine metabolism in rat brain. Neurology"},{"key":"2_CR6","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1093\/brain\/107.2.487","volume":"107","author":"RJ Hardie","year":"1984","unstructured":"Hardie RJ, Lees A J, Stern GM (1984) On-off fluctuations in Parkinson\u2019s disease: a clinical and neuropharmacological study. Brain 107: 487\u2013506","journal-title":"Brain"},{"key":"2_CR7","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1111\/j.1365-2125.1986.tb02913.x","volume":"22","author":"RJ Hardie","year":"1986","unstructured":"Hardie RJ, Malcolm SL, Lees AJ, Stern GM, Allen JG (1986) The pharmacokinetics of intravenous and oral levodopa in patients with Parkinson\u2019s disease who exhibit on-off fluctuations. Br J Clin Pharmacol 22: 429\u2013436","journal-title":"Br J Clin Pharmacol"},{"key":"2_CR8","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/S0140-6736(85)92754-0","volume":"2","author":"J Juncos","year":"1985","unstructured":"Juncos J, Serrati C, Fabbrini G, Chase TN (1985) Fluctuating levodopa concentrations and Parkinson\u2019s disease. Lancet 2: 440","journal-title":"Lancet"},{"key":"2_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00002826-198602000-00001","volume":"9","author":"JA Kaye","year":"1986","unstructured":"Kaye J A, Feldman RG (1986) The role of L-dopa holiday in the long-term management of Parkinson\u2019s disease. Clin Neuropharmacol 9: 1\u201313","journal-title":"Clin Neuropharmacol"},{"key":"2_CR10","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1002\/ana.410200213","volume":"20","author":"R Kurlan","year":"1986","unstructured":"Kurlan R, Rubin A J, Miller C, Rivera-Calmlim L, Clarke A, Shoulson I (1986) Duodenal delivery of levodopa for on-off fluctuations in parkinsonism: preliminary observations. Ann Neurol 20: 262\u2013265","journal-title":"Ann Neurol"},{"key":"2_CR11","first-page":"475","volume":"24","author":"RH McDowell","year":"1979","unstructured":"McDowell RH, Papavasiliou P, Sweet R (1979) Long-term study and the effect of human growth hormone in parkinsonian patients treated with L-dopa. Adv Neurol 24: 475\u2013488","journal-title":"Adv Neurol"},{"key":"2_CR12","first-page":"163","volume":"52","author":"MD Muenter","year":"1977","unstructured":"Muenter MD, Sharpless NS, Tyce GM, Darley FL (1977) Patterns of dystonia (\u201cI-D-I\u201d and \u201cD-I-D\u201d) in response to L-dopa therapy for Parkinson\u2019s disease. Mayo Clin Proc 52: 163\u2013174","journal-title":"Mayo Clin Proc"},{"key":"2_CR13","first-page":"1","volume":"3","author":"JG Nutt","year":"1986","unstructured":"Nutt JG (1986) Food interactions in parkinsonism. Neurol Consult 3: 1\u20134","journal-title":"Neurol Consult"},{"key":"2_CR14","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1212\/WNL.36.6.739","volume":"36","author":"JG Nutt","year":"1986","unstructured":"Nutt JG, Woodward WR (1986) Levodopa pharmacokinetics and pharmacodynamics in fluctuating parkinsonian patients. Neurology 36: 739\u2013744","journal-title":"Neurology"},{"key":"2_CR15","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1002\/ana.410180505","volume":"13","author":"JG Nutt","year":"1985","unstructured":"Nutt JG, Woodward WR, Anderson JL (1985) Effect of carbidopa on pharmacokinetics of intravenously administered levodopa: implications for mechanism of action of carbidopa in the treatment of parkinsonism. Ann Neurol 13: 537\u2013543","journal-title":"Ann Neurol"},{"key":"2_CR16","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1212\/WNL.36.9.1206","volume":"36","author":"JG Nutt","year":"1986","unstructured":"Nutt JG, Woodward WR, Carter HJ (1986) Clinical and biochemical studies with controlled-release Sinemet. Neurology 36: 1206\u20131211","journal-title":"Neurology"},{"key":"2_CR17","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1002\/ana.410210610","volume":"21","author":"JG Nutt","year":"1987","unstructured":"Nutt JG, Woodward WR, Gancher ST, Merrick D (1987) 3-0-methyldopa and the response to levodopa in Parkinson\u2019s disease. Ann Neurol 21: 584\u2013588","journal-title":"Ann Neurol"},{"key":"2_CR18","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1056\/NEJM198402233100802","volume":"310","author":"JG Nutt","year":"1984","unstructured":"Nutt JG, Woodward WR, Hammerstad JP, Carter JH, Anderson JL (1984) The \u201con-off\u201d phenomenon in Parkinson\u2019s disease: relation to levodopa absorption and transport. N Engl J Med 310: 483\u2013488","journal-title":"N Engl J Med"},{"key":"2_CR19","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S0140-6736(86)92929-6","volume":"1","author":"JA Obeso","year":"1986","unstructured":"Obeso JA, Luquin MR, Martinez-Lage JM (1986) Lisuride infusion pump: a device for the treatment of motor fluctuations in Parkinson\u2019s disease. Lancet 1: 467\u2013470","journal-title":"Lancet"},{"key":"2_CR20","first-page":"149","volume":"20","author":"JH Pincus","year":"1986","unstructured":"Pincus JH, Barry K (1986) Control of the \u201con-off\u201d phenomenon with dietary manipulation. Ann Neurol 20: 149","journal-title":"Ann Neurol"},{"key":"2_CR21","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/0024-3205(80)90085-5","volume":"26","author":"RM Post","year":"1980","unstructured":"Post RM (1980) Minireview: intermittent versus continuous stimulation: effects of time interval on the development of sensitization or tolerance. Life Sci 26: 1275\u20131282","journal-title":"Life Sci"},{"key":"2_CR22","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1212\/WNL.34.9.1131","volume":"34","author":"N Quinn","year":"1984","unstructured":"Quinn N, Parkes D, Marsden CD (1984) Control of on\/off phenomenon by continuous intravenous infusion of levodopa. Neurology 34: 1131\u20131136","journal-title":"Neurology"},{"key":"2_CR23","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/ana.410120310","volume":"12","author":"A Reches","year":"1982","unstructured":"Reches A, Fahn S (1982) 3-0-methyldopa blocks dopa metabolism in rat corpus striatum. Ann Neurol 12: 267\u2013271","journal-title":"Ann Neurol"},{"key":"2_CR24","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1212\/WNL.32.8.887","volume":"32","author":"A Reches","year":"1982","unstructured":"Reches A, Mielke LR, Fahn S (1982) 3-0-methyldopa inhibits rotations induced by levodopa in rats after unilateral destruction of the nigrostriatal pathway. Neurology 32: 887\u2013888","journal-title":"Neurology"},{"key":"2_CR25","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1136\/bmj.4.5727.93","volume":"4","author":"L Rivera-Calmlim","year":"1970","unstructured":"Rivera-Calmlim L, Dujovne CA, Morgan JP, Lasagna L, Bianchine JR (1970) L-dopa treatment failure: explanation and correction. Br Med J 4: 93\u201394","journal-title":"Br Med J"},{"key":"2_CR26","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/0009-8981(72)90456-1","volume":"37","author":"NS Sharpless","year":"1972","unstructured":"Sharpless NS, Muenter MD, Tyce GM, Owen CA (1972) 3-methoxy-4-hydroxyphenyl- alanine (3-0-methyldopa) in plasma during oral L-dopa therapy of patients with Parkinson\u2019s disease. Clin Chim Acta 37: 359\u2013369","journal-title":"Clin Chim Acta"},{"key":"2_CR27","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1212\/WNL.25.12.1144","volume":"24","author":"I Shoulson","year":"1975","unstructured":"Shoulson I, Glaubiger GA, Chase TN (1975) On-off response: clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonism patients. Neurology 24: 1144\u20131148","journal-title":"Neurology"},{"key":"2_CR28","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1212\/WNL.22.5.520","volume":"22","author":"RD Sweet","year":"1972","unstructured":"Sweet RD, Lee JE, Spiegel HE, McDowell F (1972) Enhanced response to low doses of levodopa after withdrawal from chronic treatment. Neurology 22: 520\u2013525","journal-title":"Neurology"},{"key":"2_CR29","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.25.2.177","volume":"25","author":"ES Tolosa","year":"1975","unstructured":"Tolosa ES, Martin WE, Cohen HP, Jacobson RL (1975) Patterns of clinical response and plasma dopa levels in Parkinson\u2019s disease. Neurology 25: 177\u2013183","journal-title":"Neurology"}],"container-title":["Continuous Dopaminergic Stimulation in Parkinson\u2019s Disease"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-7091-8954-2_2.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T10:10:15Z","timestamp":1606126215000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-7091-8954-2_2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1988]]},"ISBN":["9783211820346","9783709189542"],"references-count":29,"URL":"https:\/\/doi.org\/10.1007\/978-3-7091-8954-2_2","relation":{},"subject":[],"published":{"date-parts":[[1988]]}}}